肿瘤细胞治疗研究
英文原题：CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research.
CRISPR/Cas9技术已成为胰腺导管腺癌（PDAC）研究中的一种强大工具，有助于研究参与细胞信号通路、增殖、迁移、侵袭和化疗耐药的基因。
CRISPR/Cas9 技术已成为胰腺导管腺癌（PDAC）研究中的一种强大工具，推动了参与细胞信号通路、增殖、迁移、侵袭和化疗耐药的基因研究。在这篇综述中，我们讨论了 CRISPR 技术从精细编辑技术到广泛筛选方法的演变，审视了同源基因模型和基因工程小鼠模型（GEMMs）的实用性。我们还探讨了 CRISPR/Cas9 筛选如何揭示免疫-肿瘤细胞相互作用，凸显了该技术在 PDAC 研究中的多方面作用。此外，我们强调了 CRISPR 技术在 CAR-T 细胞疗法诊断中的应用，其中 CRISPR/Cas9 提高了靶向恶性细胞的精确性，同时将脱靶效应降至最低。
CRISPR/Cas9 technology has emerged as a powerful tool in pancreatic ductal adenocarcinoma cancer (PDAC) research, facilitating the study of genes involved in cell signaling pathways, proliferation, migration, invasion, and chemotherapy resistance. In this review, we discuss the evolution of CRISPR technologies from sophisticated editing techniques to broad screening methods, examine the utility of isogenic models and genetically engineered mouse models (GEMMs). We also explore how CRISPR/Cas9 screens can reveal immune-tumor cell interactions, highlighting the multifaceted role of this technology in PDAC research. Moreover, we emphasize the use of CRISPR technology in diagnostics for CAR-T cell therapies, where CRISPR/Cas9 enhances the precision of targeting malignant cells while minimizing off-tumor effects.
MEMBER ACCOUNT
登录成功会直接打开下一页。
